Henry Schein to Distribute Applied BioCode's MDx-3000 System in US

MT Newswires Live
09/08

Henry Schein (HSIC) has signed a distribution agreement to expand the availability of molecular diagnostic technology provider Applied BioCode's BioCode MDx-3000 System, Applied BioCode said on Tuesday.

Applied BioCode said the technology is an automated, high-throughput multiplex molecular diagnostic platform to support high-complexity clinical laboratories. The testing menu, the company said, includes upper respiratory and gastrointestinal infection panels, as well as a customizable menu option.

The agreement states that Henry Schein will distribute the MDx-3000 System and its associated assays to hospitals, health systems, and reference laboratories in the US, Applied BioCode said.

Financial details of the partnership were not disclosed.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10